ArticleAmerican journal of translational research2024
MS analysis of the plasma metabolome reveals major changes of amino acid and energy metabolism for early-onset schizophrenia.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeted metabolomics study on peripheral blood neurotransmitters in early-onset schizophrenia.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEarly-onset schizophrenia (EOS) is a severe and chronic mental disease that manifests during childhood and adolescence. There are currently no objective biomarkers to diagnose this psychosis. Recent research has shown that metabolic disorders are closely associated with the onset of schizophrenia, but there is a lack of evidence among children and adolescent populations. This study will analyze the metabolic characteristics of patients with early-onset schizophrenia through plasma metabolomics.
methodsWe analyzed plasma from 13 EOS patients and 15 healthy controls using ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOF/MS) technology to identify potential biomarkers for EOS. The discriminative potential biomarkers in delineating EOS patients from controls.
resultsA total of 22 different metabolites were found to be effective in differentiating EOS patients from healthy controls. EOS patients demonstrated statistically significant differences compared to the healthy control group, with 6 metabolites registering lower levels and 16 metabolites showing higher levels (P < 0.05). The main metabolic pathways involved include arachidonic acid metabolism, histidine metabolism, non-natural amino acid metabolism, tryptophan metabolism, and metabolism of exogenous substances mediated by cytochrome P450.
conclusionsThese metabolites suggest that disturbances in amino acid and energy metabolism may be involved in the pathogenesis of EOS. The findings provide important clues for further understanding the pathogenesis of EOS and offer potential biomarkers for the diagnosis and treatment of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.